Sökning: WFRF:(Roncolato Felicia T.)
> (2017) >
Reducing Uncertaint...
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study
-
- Roncolato, Felicia T. (författare)
- University of Sydney, Australia; ANZGOG, Australia; Macarthur Cancer Therapy Centre, Australia
-
- Joly, Florence (författare)
- Centre Francois Baclesse, France
-
- OConnell, Rachel (författare)
- University of Sydney, Australia
-
visa fler...
-
- Lanceley, Anne (författare)
- UCL, England
-
- Hilpert, Felix (författare)
- UKSH, Germany
-
- Buizen, Luke (författare)
- University of Sydney, Australia
-
- Okamoto, Aikou (författare)
- Jikei University, Japan
-
- Aotani, Eriko (författare)
- Kitasato Academic Research Org, Japan
-
- Pignata, Sandro (författare)
- IRCCS, Italy
-
- Donnellan, Paul (författare)
- Galway University Hospital, Ireland
-
- Oza, Amit (författare)
- University of Toronto, Canada
-
- Åvall-Lundqvist, Elisabeth, 1957- (författare)
- Karolinska Institutet,Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Karolinska Institute, Sweden
-
- Berek, Jonathan S. (författare)
- Stanford Comprehens Cancer Institute, CA USA
-
- Heitz, Florian (författare)
- KEM, Germany; KEM, Germany
-
- Feeney, Amanda (författare)
- Cancer Research UK, England; UCL Cancer Trials Centre, England
-
- Berton-Rigaud, Dominique (författare)
- ICO Centre Rene Gauducheau, France
-
- Stockler, Martin R. (författare)
- University of Sydney, Australia; ANZGOG, Australia
-
- King, Madeleine (författare)
- ANZGOG, Australia; University of Sydney, Australia
-
- Friedlander, Michael (författare)
- ANZGOG, Australia; Prince Wales Hospital, Australia
-
visa färre...
-
(creator_code:org_t)
- 2017-06-08
- 2017
- Engelska.
-
Ingår i: The Oncologist. - : WILEY. - 1083-7159 .- 1549-490X. ; 22:9, s. 1117-1124
- Relaterad länk:
-
https://theoncologis...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background. Clinicians and patients often overestimate the benefits of chemotherapy, and overall survival (OS), in platinum resistant/refractory ovarian cancer (PRROC). This study sought to determine aspects of health-related quality of life and clinicopathological characteristics before starting chemotherapy that were associated with stopping chemotherapy early, shortened survival, and death within 30 days of chemotherapy. Materials and Methods. This study enrolled women with PRROC before starting palliative chemotherapy. Health-related quality of life was measured with EORTC QLQ-C30/QLQ-OV28. Chemotherapy stopped within 8 weeks of starting was defined as stopping early. Logistic regression was used to assess univariable and multivariable associations with stopping chemotherapy early and death within 30 days of chemotherapy; Cox proportional hazards regression was used to assess associations with progression-free and OS. Results. Low baseline global health status (GHS), role function (RF), physical function (PF), and high abdominal/gastrointestinal symptom (AGIS) were associated with stopping chemotherapy early (all pamp;lt;.007); low PF and RF remained significant after adjusting for clinicopathological factors (both pamp;lt;.0401). Most who stopped chemotherapy early had Eastern Cooperative Oncology Group Performance Score 0-1 at baseline (79%); PF, RF, and GHS remained independently significant predictors of stopping chemotherapy early in this subgroup. Death within 30 days of chemotherapy occurred in 14%. Low-GHS, RF, and PF remained significantly associated with death within 30 days of chemotherapy after adjusting for clinicopathological factors (all pamp;lt;.012). Conclusion. Women with low GHS, RF, or PF before starting chemotherapy were more likely to stop chemotherapy early, with short OS. Self-ratings of GHS, RF, and PF could improve patient-clinician communication regarding prognosis and help decision-making in women considering chemotherapy for PRROC.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Patient-reported outcomes; Prognosis; Platinum-resistant ovarian cancer; Quality of life
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Roncolato, Felic ...
-
Joly, Florence
-
OConnell, Rachel
-
Lanceley, Anne
-
Hilpert, Felix
-
Buizen, Luke
-
visa fler...
-
Okamoto, Aikou
-
Aotani, Eriko
-
Pignata, Sandro
-
Donnellan, Paul
-
Oza, Amit
-
Åvall-Lundqvist, ...
-
Berek, Jonathan ...
-
Heitz, Florian
-
Feeney, Amanda
-
Berton-Rigaud, D ...
-
Stockler, Martin ...
-
King, Madeleine
-
Friedlander, Mic ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
The Oncologist
- Av lärosätet
-
Linköpings universitet
-
Karolinska Institutet